Krebs Biochemicals & Industries Ltd (KREBSBIO) — FY26 Annual Report | 4 September 2026

Krebs Biochemicals & Industries Limited reported a consolidated net loss of ₹1,693.31 Lakhs for FY 2025-26, narrowing from ₹2,693.93 Lakhs loss in FY 2024-25. The company recorded total income of ₹2,575.79 Lakhs, driven by revenue from operations of ₹2,373.16 Lakhs and other income of ₹202.63 Lakhs. Profit before tax stood at a loss of ₹1,693.31 Lakhs, with no exceptional items. The Board highlighted ongoing operational challenges, including the closure of the Vizag manufacturing unit since February 2025 due to pollution control orders, and emphasized efforts to revoke the order and restart operations. Management noted that the company is pursuing strategic initiatives, including potential contract manufacturing and new product development, to improve utilization of idle capacity and achieve breakeven. The Board recommended no dividend for the year. The filing also detailed related party transactions with promoter Ipca Laboratories Limited, including a proposed resolution for approval of transactions up to ₹120 Crores annually, and ratified remuneration for cost auditors. The AGM is scheduled for 29 September 2026 via VC/OAVM, with remote e-voting available from 25 September to 28 September 2026.